3D bioprinting for reconstituting the cancer microenvironment. by Datta, Pallab et al.
The Jackson Laboratory 
The Mouseion at the JAXlibrary 
Faculty Research 2020 Faculty Research 
7-27-2020 





Ibrahim T Ozbolat 
Follow this and additional works at: https://mouseion.jax.org/stfb2020 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
REVIEW ARTICLE OPEN
3D bioprinting for reconstituting the cancer microenvironment
Pallab Datta1, Madhuri Dey2, Zaman Ataie 3, Derya Unutmaz4 and Ibrahim T. Ozbolat 3,5,6,7✉
The cancer microenvironment is known for its complexity, both in its content as well as its dynamic nature, which is difficult to
study using two-dimensional (2D) cell culture models. Several advances in tissue engineering have allowed more physiologically
relevant three-dimensional (3D) in vitro cancer models, such as spheroid cultures, biopolymer scaffolds, and cancer-on-a-chip
devices. Although these models serve as powerful tools for dissecting the roles of various biochemical and biophysical cues in
carcinoma initiation and progression, they lack the ability to control the organization of multiple cell types in a complex dynamic
3D architecture. By virtue of its ability to precisely define perfusable networks and position of various cell types in a high-
throughput manner, 3D bioprinting has the potential to more closely recapitulate the cancer microenvironment, relative to current
methods. In this review, we discuss the applications of 3D bioprinting in mimicking cancer microenvironment, their use in
immunotherapy as prescreening tools, and overview of current bioprinted cancer models.
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INTRODUCTION
The escalating cost of drug development is a deterrent for
conducting clinical trials, leading to a decrease in number of
innovative treatments. For example, in oncology, the success rate
of drugs entering clinical trials and obtaining Food and Drug
Administration approval is only 5.1% (ref. 1). This situation offers
an opportunity to stimulate the development of physiologically
relevant tissue models with improved preclinical testing out-
comes. Monolayer culture of cancer cells in two-dimensional (2D)
environment is the simplest approach for in vitro cancer studies.
Generally, 2D in vitro models represent only an oversimplified
version of in vivo conditions and are not able to address many
physiological questions. The tumor microenvironment is char-
acterized by a bidirectional communication between the myriad
cellular and noncellular components. Apart from biochemical
signaling, various physical signaling like extracellular matrix (ECM)
stiffness, topography, pattern, and interstitial flow, shear stresses,
or fluid forces can influence the development of tumors. In a
tumor lesion, an aberrant vascularization leads to oxygen, nutrient,
and metabolic waste gradients causing the development of a
necrotic core2. The cells in the core area adapt to a quiescent
condition and are difficult to eradicate3. They also secrete hypoxia-
inducible factors and other cytokines, which can alter the
physiology of neighboring cells. Furthermore, cell–ECM interac-
tions in the form of ECM remodeling, and recruitment of
fibroblasts and perivascular and immune cells govern the
metastasis behavior of malignant cells4. Thus, reconstruction of
the complex microenvironment assumes great significance in
modern cancer biology, which can be attempted in a three-
dimensional (3D) model. Several approaches have been devel-
oped for 3D modeling of the tumor microenvironment, including
spheroid culture, biopolymer scaffolds, and cancer-on-a-chip
platforms. However, these models lack the capability to precisely
control the location and organization of various cellular compo-
nents in a tumor microenvironment.
3D bioprinting and its virtue in mimicking the tumor
microenvironment
3D bioprinting is defined as the layer-by-layer deposition of
bioinks, such as tissue spheroids, cell pellets, microcarriers,
decellularized ECM (dECM) components, and cell-laden hydrogels,
in a spatially defined manner as per a computer-aided designed
structure to generate viable 3D constructs. In the last decade,
bioprinting technologies have undergone remarkable advance-
ments. Bioprinting modalities comprise of extrusion-based bio-
printing (EBB), droplet-based bioprinting (DBB), and laser-based
bioprinting (LBB), which have been described in details else-
where5,6. EBB relies on robotic dispensing of continuous stream of
bioinks under pneumatic- or motor-driven forces. The DBB
modality, e.g., inkjet bioprinting, is based on deposition of
droplets under thermal, piezoelectric, or solenoid-based mechan-
ical actuation. LBB, generates constructs by deposition of bioinks
in a pattern defined by a laser path. Bioprinting can be performed
either in a scaffold-free or scaffold-based manner. In the scaffold-
free approach, cell pellets or aggregates are bioprinted on a
sacrificial material mold, such as alginate or agarose, which is
discarded once the bioprinted tissue matures and subsequently
deposits its own ECM components. In the scaffold-based
approach, a 3D construct is printed using a bioink that comprises
of cells encapsulated in a hydrogel. Scaffold-based bioprinting
then relies on the degradation kinetics, as well as cell–material
interactions to direct tissue growth7–12. We highlight the major
advantages that bioprinting hold over other biofabrication
techniques in the ensuing section.
Advantages of bioprinting in reconstitution of the tumor
microenvironment
Spatial control on matrix properties. ECM mechanics, such as
matrix stiffness, plays a major role in the metastatic behavior of
cancer cells and this factor can be incorporated in a 3D bioprinted
tumor model13. 3D constructs of polyethylene glycol (PEG)-based
log-pile micro architecture was formed with variable stiffness
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(0.9–5.5 MPa) for cell migration study14. 3D honeycomb structures
resembling rat capillaries were also formed using the same
method by the same group15. The effect of matrix stiffness and
vessels diameter on cellular migration was tested, and the study
showed that the migration speed of normal cells remained
unaffected with altered vessel diameter, whereas the speed of
HeLa cell migration considerably decreased with increasing vessel
diameter16. In bioprinted cancer models, a gradient of hydrogel
matrix was also developed in 3D to facilitate directional cell
migration via controlled deposition of bioink mimicking the
physiochemical environment of cancer cells17.
In addition to stiffness, spatial distribution of biochemical
factors can also be mediated to mimic the native tumor
microenvironment. Freeform reversible embedding of suspended
hydrogels (FRESH) is one of the recent techniques of EBB methods
for mimicking the complex native architecture of biological
tissues18,19. Employing the FRESH technique, a neuroblastoma
model was developed with sodium alginate20. Biomolecular
gradient was facilitated through the release of 3D printed
stimuli-responsive capsules. Such capsules consisted of an
aqueous core of biomolecules coated with a poly(lactic-co-
glycolic) acid-based polymer shell17. The capsules were loaded
with plasmonic gold nanorods in the shell, which enabled
selective rupture and release of biomolecules by controlling the
wavelength of irradiation. Thus, 3D bioprinting facilitated precise
control over location of these capsules in a hydrogel, which makes
it a suitable carrier of biomolecular payloads. However, to obtain
spatial control of matrix properties, it is essential to employ the
scaffold-based bioprinting approach necessitating optimization of
material properties, such as hydrogel density as well as
biocompatibility, cell–material interactions, and chances of toxicity
induced by scaffold degradation products. Moreover, different
bioprinting approaches need to be developed involving multi-
material bioprinting, or gradient-based material deposition to
study cancer metastasis across soft to hard tissue interfaces, such
as breast cancer metastasis to bone, lungs, or brain.
Ability to integrate perfusable vascular networks. Bioprinting has
been leveraged for fabrication of both blood vessels as well as
vascularized tissues. This can be accomplished by either a scaffold-
based or scaffold-free approach. In scaffold-based approach, the
cell–biomaterial interactions with hydrogels assume significance
and limit the number of cells in constructs, whereas scaffold-free
method relies on self-assembly and fusion of cell aggregates. In
the literature, all the three bioprinting modalities have been
extensively explored for fabrication of vascular networks21. Often,
bioprinting with a sacrificial bioink, which is dissolved subse-
quently to leave behind a porous network, have found utility as
stand-alone bioprinting of overhang structures, which are usually
difficult to fabricate. In this context, bioprinting based on a
support bath have also attracted considerable attention21. The
support bath provides a semisolid medium onto which water-rich,
low viscosity bioinks can be bioprinted, overcoming the limita-
tions of printing over flat air interfaces. Bioprinting in suspension
bath is particularly attractive to fabricate structures, which can
self-support themselves22. Perfusable vascular structures were
incorporated in 3D architectures for studying the invasion of
cancer cells through vessels. For recapitulating the initiation of
cancer spreading, several chemometric pathways that guide
cellular invasion and angiogenesis, can be programmed. For
reconstructing the tumor microenvironment, individual 3D
bioprinted components can be assembled from droplets of tumor
cells obtained from primary tumor site, microchannels comprising
endothelial cells, fibroblast containing hydrogel acting as tumor
stroma, and programmable capsules for releasing chemical
signals23. The effect of micro-scale architecture and mechanical
fluid microenvironment on cancer cell phenotype, molecular
signaling, cell cycle, gene expression, and functionality has been
studied24. It was demonstrated that G2/M cell cycle arrest occurs
under shear stress of the order of 12 dynes/cm2, whereas static
culture conditions cause G0/G1 arrest. Decreased expressions of
certain cyclins, and cyclin-dependent protein kinases mediated by
αvβ3 and β1 integrins through Smad1 and Smad5 was observed
as the probable pathway, thus providing a basis for relating
mechanical cues with cell functions.
High-throughput fabrication of cancer models. Automation and
high-throughput assay capabilities for metabolism, and toxicology
are important processes for drug discovery and development.
Presently, high-throughput screening (HTS) is performed with 2D
cell cultures in multi-well plates. Hundreds to thousands of lead
compounds can be tested in 96-well arrays, using small volumes
and weights of candidate compounds by fast, mechanically
controlled processes. However, quantification techniques in HTS,
such as absorbance, or fluorescence measurements, need
extensive standardization. HTS assays have been tremendously
improved due to improvements in molecular biology and
genomics, yielding phenotypically and genotypically well-
characterized disease models and bioreactors with scalable
culture characteristics. As the advantages of 3D culture over 2D
cultures become more apparent and the role of heterogeneous
tumor microenvironment comprising multiple cell types and
cell–material interactions assume significance, bioprinting is
emerging as a potential method for HTS assays, which can
provide rapid process flows with higher consistency and increased
sample volumes over manual deposition. Therefore, the bioprint-
ing community also becomes sensitive to the needs for HTS, and
improvements in process flow times, resolution, bioprinting
speeds, as well as quantification techniques are pursued25.
Amongst different bioprinting modalities, DBB is particularly
suited for HTS fabrication. The modality can eject the bioinks
from print heads in a highly synchronized manner at rates of
∼1000 droplets per second, to deposit 50–100 μm droplets
maintaining high cell viability26. In contrast, LBB can achieve
throughput rates of up to 20 Hz. Though, some DBB processes,
such as inkjet bioprinting, can achieve higher printing speeds,
droplet instabilities has been observed at high frequencies.
Despite this fact, DBB has substantial potential to generate tumor
tissue models in a high-throughput manner for use in HTS. Using
various bioprinting modalities, in vitro models of standard 384-
and 1536-well plate sizes27 have been reported. With respect to
bioprinting to obtain HTS models, it is also necessary to
standardize the assay end points, which will correlate with patient
outcomes. Compared to 2D models, assays in 3D models is more
challenging since the quantification of whole-construct flores-
cence or spectroscopy readouts do not provide information at
cellular-level resolution, critical for co-culture and investigations of
heterotypic cell–cell interactions25.
3D BIOPRINTED CANCER MODELS
In the forthcoming section, the progress made in in vitro models
of different types of cancer fabricated by bioprinting are described
in details. A summary of these achievements for each cancer
model indicating the cell types, bioink, or substrate and the
bioprinting modality used along with their major advantages/
limitations are presented in Table 1.
Glioblastoma
Glioblastoma (GBM) is the most common aggressive form of
cancer affecting the central nervous system. It forms from star-
shaped cells called astrocytes, present in the brain and spinal cord.
GBM tumors are usually surgically removed followed by radio-
therapy, chemotherapy, and other comprehensive treatment
methods. However, patients often suffer from relapse of tumors
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caused by the drug resistance of glioma cells. Thus, it is essential
to investigate the drug response of glioma cells using a suitable
in vitro model. In this regard, a representative 3D bioprinted
model, ‘glioblastoma-on-a-chip’, was established using patient-
derived glioblastoma cells co-cultured with endothelial cells on
dECM environment. In this model, a cancer-stroma concentric-ring
structure was developed, which maintained the radial oxygen
gradient and mimicked the in vivo tumor-like microenvironment
(Fig. 1). The model showed clinical significance by reproducing
patient-specific resistance to concurrent chemoradiation and
temozolomide drug. Such a model may serve as the purpose of
screening of effective treatment modalities for glioblastoma
patients, who are resistant to conventional treatments28. In several
studies, drug resistance models were extrusion bioprinted,
employing human glioma stem cells encapsulated in alginate or
gelatin-based hydrogels29,30. Higher drug resistance was observed
for the 3D models as compared to 2D. Furthermore, inkjet
bioprinting was also used to print a co-patterned hepatoma and
glioma cell-based model to observe the anticancer activity of the
drug tegafur on the glioma cells31. Apart from chemoresistance,
Table 1. 3D bioprinted cancer models.





Glioblastoma-on-a-chip Glioma cell line U118 and endothelial cells Collagen or dECM
hydrogel
EBB 28
Glioma stem cell (shell); glioma cell line (core) Alginate Coaxial EBB 29
Glioma stem cells Gelatin, alginate, and
fibrinogen
EBB 30
Hepatoma HepG2 and glioma cell U251 Alginate DBB (Inkjet) 31
iPSC-derived human neural progenitor cells and U118 human glioma cells Scaffold-free 3D
culture
EBB 32
Human glioma stem cell line, U118 Sodium alginate and
gelatin
EBB 33
Glioblastoma-associated macrophages (GAMs) and glioblastoma cells GelMA EBB 34
Human primary umbilical cord-derived mesenchymal stromal cells
(UC-MSC, referred to as MSCs), HUVEC, and human bone marrow-derived




Breast tumor model Immortalized non-tumorigenic human breast epithelial cell lines MCF-12A
and MCF10A
Rat tail collagen I EBB 36
MCF-7 BC cells PBS solution DBB 101
Immortalized non-tumorigenic human breast epithelial cell line, MCF-12A,
and the breast carcinoma cell lines MCF-7 and MDA-MB-468
Rat tail collagen EBB 37
MCF-7 cell Gelatin-PEG DBB 38
BT474 breast cancer cells, human perinatal foreskin fibroblasts (BJ), and















Mouse fibroblast (L929) Alginate EBB 42
Breast cancer cell lines of distinct subtypes, luminal (MCF-7), basal like
(HCC1143), HER2 amplified (SKBR3), and claudin low (MDA-MB-231)
Alginate and gelatin EBB 43
IMR-90 fibroblast cells and MDA-MB-231 cancer cells Alginate and gelatin EBB 44
Primary human bone marrow MSCs, BrCa cell line GelMA and nHA LBB 45
MDA-MB-231; human bone marrow stromal cells Modified nHA EBB 104
Metastatic breast cancer cell line MDA-MB-231











Pancreatic cancer and stellate cells, endothelial cells Alginate and gelatin EBB 48
Ovarian cancer Ovarian cancer OVCAR-5 and (MRC-5) fibroblasts Matrigel DBB 49,50





Cervical tumor Hela cells Gelatin, alginate, and
fibrinogen
EBB 51
Hepatocarcinoma model Human perinatal foreskin fibroblasts and human adult dermal fibroblasts Liver dECM LBB 55
C3H/10T1/2, clone 8 cells, and GFP-expressing human neonatal dermal
fibroblast cells; HUVECs and RFP-HUVECs
GelMA EBB 56
P Datta et al.
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tumor cell invasion into surrounding parenchymal tissue, post-
surgery, is another driving factor for low response rates in glioma.
This phenomenon was studied using 3D bioprinting combined
with a scaffold-free culture technique. 3D confocal microscopy
was used to observe glioma cell invasion into neural-like tissue
spheroid derived from rodent neural progenitor cells32. Bioprinted
tumor models were also developed to enhance the stemness
properties of glioma cells, as glioma stem cells are an important
mediator of cancer resistance. The model elucidated
epithelial–mesenchymal transition and possible mechanism of
glioma stem cells enhancement. A marked difference was evident
in the drug resistance and in vivo tumorogenicity of cells when
compared to 2D (ref. 33). Further, to study cellular interaction, a 3D
bioprinted mini-brain model was developed by Heinrich et al.
incorporating glioblastoma-associated macrophages (GAMs) and
glioblastoma cells in glioblastoma multiforme. In this model,
macrophages were actively recruited by glioblastoma cells, and
metamorphosed into a typical GAM phenotype and upregulation
of several genes, which was found to compare well with the
transcriptomic analysis of over 150 patients with GBM. The
macrophages were shown to be inducing the proliferation and
invasion of glioblastoma cells. The bioprinted tumor model was
also applied to study the inhibitory effect of drugs on GAMs and
tumor cells34.
Fig. 1 GBM-on-a-chip. a Schematic representation of a tumor cross-section depicting the hypoxic core and different biological components
typically found in a tumor microenvironment. b Schematic illustration of the bioinks used to fabricate a compartmentalized GBM-on-a-chip
model. c Mock representation of bioink compartments of brain dECM laden with HUVECs (depicted in magenta), and brain dECM with GBM
cells (blue) shown from above (top) and from the corner (bottom; scale bar, 2 cm). d Computer simulation of oxygen gradient along A–A′
cross-section depicted by time-lapse jet colourmap images. e Schematic representation of the various regions within the printed GBM model
(i) core, (ii) intermediate, (iii) peripheral regions, and (iv) the surrounding tissue region. f Fluorescent images of cross-section of
immunostained tumor highlighting the hypoxic cells using pimonidazole (PM), Ki67 for the proliferating cells, and DAPI for the cell nuclei
(scale bar, 200 μm.) (Reproduced/adapted with permission from ref. 28).
P Datta et al.
4
npj Precision Oncology (2020)    18 Published in partnership with The Hormel Institute, University of Minnesota
Breast cancer
Breast cancer is one of the most leading type of invasive cancer.
This is a heterogenous cancer type and is aggravated due to the
presence of a small population of stem cells that cause resistance
to chemotherapy or radiation treatment, and result in recurrence.
While considerable progress has been made in treatment of
localized tumors, severe bottlenecks need to be overcome to
remedy metastatic or recurrent cases. Importantly, breast cancer
niche is characterized by the presence of surrounding ECM,
endothelial and immune cells, fibroblasts, and adipocytes, which
have established role in tumor progression35. Thus, there exists a
constant need to study the breast tumor microenvironment and
as such has also been studied using 3D bioprinting techniques. As
organoid culture is one of the most promising techniques for
studying cancer progression, a study was conducted by Reid et al.
to fabricate breast tumor organoids employing bioprinting. In this
study, a small number (as few as ten cells) of breast cancer cells
was bioprinted in a single print and individual organoids were
printed 500 μm apart. Bioprinted cells further fused and formed
single layer of mammary cells and developed ~3mm contiguous
lumen circles36. On comparing a 2D and 3D bioprinted breast
cancer model, bioprinted MCF-7 cells produced increased levels of
chaperone proteins (like, HSP70 and HSP90), in the presence of
high concentration of tamoxifen, thus closely mimicking native
tumors. In a 3D bioprinted collagen model, biomimetic chimeric
organoids were developed by co-bioprinting breast cancer cells
and normal mammary epithelial cells. Comparing both structures
(depicted in Fig. 2), the study showed the significant increase of
5-hydroxymethylcytosine in chimeric structure than the tumoroid
one37. In other studies, breast cancer spheroids were formed on
PEG-diacrylate concave structures through LBB (refs. 38,39). In long-
term culture conditions, spheroids showed hypoxic core with the
presence of necrotic cells. The close resemblance with patholo-
gical conditions enables the use of such a model as an efficient
drug screening tool. Thus, 3D tumor spheroid models hold
prospects to study microenvironmental control over tumorogen-
esis of breast cancer cells.
Scaffold-based 3D cancer models have also been widely used to
study the effect of anticancer drugs. In this aspect, a 3D bioprinted
breast cancer model was fabricated using primary breast cancer cells
(21PT) and adipose-derived stem cells (ADSCs) and cellular responses
were observed under the treatment of doxorubicin (DOX). Such a
model allowed the establishment of a direct relationship between
the thickness of ADSCs and their resistance to DOX (ref. 40). In
another study, bioprinted spheroids were found to be more resistant
to paclitaxel compared to the individually bioprinted cells41.
In most 3D cancer models, absence of stroma and immune cells
fails to mimic the tumor microenvironment. A recent development
sequentially incorporated both cancer and stromal cells in 3D
hydrogels, where the volumetric viability of cells was determined
through fluoro-D-oxy glucose staining and positron emission
tomography–computerized tomography after three days of
culture42. In another study, Langer et al. introduced a 3D
bioprinted tumor model consisting of multiple cell types,
including fibroblasts, adipocytes, patient-derived cancer cells,
and endothelial cells, to examine the interaction between cancer
Fig. 2 Chimeric organoids fabricated using bioprinting. a Formation of chimeric organoids was significantly better when 3D bioprinted
compared to standard culture methods. ***p < 0.001 by two-way ANOVA. b–d Large chimeric organoids bioprinted in a circular pattern with
500 µm space between them, consisting of 5:1 ratio of MCF-12A (red) and MDA-MB-468 (green) cells at day 3 (b), day 7 (c), and day 21 (d). e, f A
300 µm spaced alternating prints of tumorigenic MDA-MB-468 cells (green) and MCF-12A cells (red) at day 1 (e) and day 7 (f) demonstrating
incorporation of cancer cells into the organoid (scale bars: b–d= 500 µm; e and f= 200 µm; reproduced/adapted with permission from ref. 37).
P Datta et al.
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and stromal cells (Fig. 3)43. This heterocellular tumor model
recapitulated different aspects of neoplastic tissues and also
allowed the investigations of cellular responses by manipulating
tumor microenvironment under therapeutic interventions. Simi-
larly, using a alginate/gelatin-based 3D bioprinted breast cancer
model containing fibroblasts and MDA-MB-231 cancer cells,
separated through a partition, showed spheroid formation of
cancer cells and migration of fibroblasts to those spheroids44.
The normal mammary microenvironment can suppress tumor-
ogenesis and redirect cancer cells to adopt a normal mammary
epithelial cell fate in vivo. The interaction between breast cancer
cells with bone stromal cells was studied in gelatin-methacrylate
hydrogel environment with bone-mineral-mimetic nano-
hydroxyapatite (nHA) composite45. The co-culture model showed
enhanced proliferation of breast cancer cells and reduced
proliferation of mesenchymal stromal cells (MSCs)/osteoblast cells.
By changing different biophysical parameters (such as thickness,
composition, etc.) of scaffolds, this study demonstrated the
metastatic behavior of breast cancer cells in the presence of
bone cells. Breast cancer cells, co-cultured with bone marrow stem
cells in a 3D bioprinted hydrogel-hydroxyapatite composite
scaffolds46, favored spheroid formation, and proliferation of breast
cancer cells, signifying the influence of stem cells in metastatic
progression of cancer cells. Moreover, cancer cells in 3D showed
higher resistance to chemotherapy drug in comparison to cells in
2D (ref. 47). Such models can aid in predicting the role of
metastatic behavior of cancer cells on remodeling of bone tissue.
Pancreatic adenocarcinoma
Pancreatic adenocarcinoma is an exocrine tumor occurring in the
cells that line up the pancreatic duct. It spreads rapidly, has poor
prognosis, and is undetected in early stages of the disease. This
combined with therapeutic resistance makes the treatment of the
disease extremely difficult. As 2D models do not recapitulate the
pancreatic microenvironment correctly, a 3D bioprinted organo-
typic pancreatic adenocarcinoma model was fabricated using
pancreatic cancer cells inside a microenvironment, consisting of
endothelial and pancreatic stellate cells by Sears et al.48. In
another study by Langer et al., efforts were also made in
bioprinting scaffold-free tumors using patient-derived cells to
examine if the growth and development of pancreatic cells could
be recapitulated in vitro43. This model was able to mimic many
features of tumor, including response to extrinsic signals and
in vivo morphology.
Ovarian and cervical cancer
Ovarian or cervical cancer usually goes undetected in early stages
and mostly diagnosed after the cancer spreads to other organs.
Similar to other cancer types, ovarian or cervical cancer also
presents a heterogenous microenvironment, which is difficult to
recapitulate using 2D models. In this regard, a high-throughput
bioprinting system was used to construct a tumor model on
Matrigel substrate by co-bioprinting ovarian cancer cells (OVCAR-
5) and fibroblasts (MRC-5). The authors observed the alteration in
formation of micro-nodules by OVCAR-5 cells in the co-culture
model as well as a parallel model, in which certain distance was
maintained between OVCAR-5 and fibroblast cells49. These 3D
models exhibited different sensitivity to co-therapy of
benzorphyrin-mediated photodynamic therapy and carboplatin
administration50. In another study, human cervical carcinoma
(HeLa) cells, encapsulated in a mixture of fibrinogen, alginate, and
gelatin, were bioprinted using EBB method, as shown in
Fig. 3 Breast cancer cells were extrusion bioprinted into a stromal mix of primary human mammary fibroblast and human umbilical vein
endothelial cells (HUVECs). a Representative H&E images of bioprinted tissues, fixed on day 10. b Trichrome staining of bioprinted tissues.
Scale bars, 500 µm. d Immunofluorescence images of bioprinted tissue sections, stained for KRT8/18 (green), VIM (red), and CD31 (yellow;
reproduced/adapted with permission from ref. 43).
P Datta et al.
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Fig. 4 (ref. 51). In comparison to 2D, differences were evident in the
bioprinted model with respect to proliferation, matrix metallo-
proteinase (MMP), and chemoresistance to paclitaxel markers. 3D
spheroid formulation was also observed, possibly due to the
enhanced intercellular and cell–material interactions. Biofabri-
cated ovarian cancer models (Fig. 5) have also been developed
using a LBB method, which demonstrated the perfusion
characteristics and metabolic behavior of ovarian cancer cells52.
A dose–response curve was generated for DOX and application of
in situ microscopy was also demonstrated for quantitative
bioassay with the model. The application of the model was also
demonstrated for imaging of microparticle flow inside hydrogel
constructs.
Hepatocarcinoma
Hepatocellular carcinoma (HCC) is one of the most common
malignant forms of cancer and the second largest cause of
mortality worldwide53. It is usually characterized by the develop-
ment of stiff hepatocellular nodules, where the liver ECM stiffness
is found to be greater than that of healthy liver parenchyma54. A
3D hepatocarcinoma model was fabricated by Ma et al. through a
two-step stereolithographic bioprinting method as illustrated in
Fig. 6 (ref. 55). They patterned liver dECM with tailorable
mechanical properties, which formed hexagonal lobular structure
containing human iPSC-derived hepatic progenitor cells (HPCs)
and endothelial cells. This served as a platform for HCC
progression study. The iPSC-derived HPCs in 3D triculture
exhibited differential expression of genes correlated with secre-
tion of liver-specific proteins like transthyretin, hepatocyte nuclear
factor 4α, albumin corresponding to the different stages of cellular
maturation inside the constructs. The cells in 3D constructs also
exhibited increased basal cytochrome P450 levels, indicating adult
hepatocytes maturation and induction by rifampicin of certain
subtypes of this enzyme system was also evidenced, suggesting
development of a physiologically relevant construct. This model
can be further improved to large-scale hepatic disease model by
inclusion of ECM cues, patient-derived diseased cells, and
functional vasculature. In another study, Kolesky et al.56 estab-
lished a 3D printed hepatocarcinoma model using an alternative
approach. They used a multi-nozzle printing device through which
Pluronic F127 (a tri-block copolymers of poly(ethylene oxide)-poly
(propylene oxide)-poly(ethylene oxide)) was printed using one
nozzle head, and other nozzles were used for bioprinting HepG2
and human umbilical vein endothelial cell (HUVEC) containing
hydrogels. Thus, a highly scalable platform was developed for
generating engineered tissue constructs containing vascular
channels and multiple cell types inside the ECM milieau.
Table 1 summarizes the cancer models fabricated with the use
of different bioprinting techniques and bioink materials.
INTEGRATION OF BIOPRINTING WITH MICROFLUIDICS
Bionic engineering integrating the principles of microfluidics and
3D bioprinting with co-culture techniques can improve the
effectiveness of in vitro tumor models for disease biology and
drug testing. For developing the complex heterogeneous tumor
microenvironment, the integration of microfluidics with bioprint-
ing is an emerging approach. Fluid flow can be introduced
through microfluidic systems, which recapitulates the dynamic
tumor microenvironment. Studies have proven that interstitial
fluid flow around the tumor tissue creates shear stress, which
arrests the cell cycle progression of cancer cells24 and cancer cells
also exhibit tendencies to migrate toward the direction of fluid
flow57. Microfluidic system can create different flow patterns and
chemical gradients, which is effective to study the metastatic
behavior of cancer cells.
Huang et al. fabricated microchannels in dimensions of 25, 45,
and 120 µm using bioprinting, and studied the migration of
cancerous HeLa cells15 and noncancerous 10T1/2 cells. The
migration speed of HeLa cells was increased in smaller channels,
whereas no differences in the speed was observed for 10T1/2 cells.
In another work, Soman et al. fabricated polyethyleneglycol
diacrylate (PEGDA)-based 3D log-pile structures14 and tuned the
stiffness by changing the prepolymer concentration. Transformed
cells showed higher migration velocity in this matrix as compared
to normal epithelial cells, a behavior which cannot be observed
under 2D conditions58. The feasibility of microfluidics integration
was exemplified by fabrication of a hepatoma model in which the
cluster size could be controlled and demonstrated for efficacy
testing of Metuzumab, an anti-CD147 monoclonal antibody.
Compared to a bioprinted-only in vitro model, hepatoma cells in
the dynamic microfluidic model proliferated at a faster rate.
Simultaneously, compared to 2D models, 3D model exhibited
higher drug dosage dependant tolerance of growth and
metastasis, which bear closer resemblance to trends observed in
preclinical animal experiments as well as clinical trials of anti-
CD147 antibody drugs. Further, investigations revealed that if the
said model was improved by including peripheral blood mono-
nuclear cells (PBMC) as effector cells and antibody-dependent cell-
mediated cytotoxicity in pharmacology of these antibody drugs, a
higher effectiveness of the antibody-dependent cell-mediated
cytotoxicity tests under same drug dose in the integrated
microfluidic-3D bioprinting models could be obtained59.
The integration of bioprinting with microfluidics can be
performed in two principal approaches. In the first approach,
bioprinting can be performed with microfluidic-modified printing
nozzles. This can overcome some of the limitations of conven-
tional bioprinting methods like the ability to precisely deposit
multiple cell types inside a single bulk tissue, and reduce the
mechanical- or thermal-forces induced damages to cell pheno-
types. Such microfluidic-modified bioprinting has been demon-
strated for fabrication of vascular channels and aligned muscle
tissue constructs60. In the second approach, bioprinting can be
carried out directly on a microfluidic-patterned receiving well
plates. Such models have been built for co-patterned hepatoma
and glioma cells, in which the anticancer effect of a drug tegafur
was analyzed on glioma cells after metabolized by HepG2 cells61.
Bioprinting has also been employed for developing microfluidic
chips. For example, direct cell writing has been used to fabricate
micro-organs inside soft-lithography-generated polydimethyl
siloxane (PDMS) microfluidic chips62,63. Direct cell writing is one
of the most convenient methods to fabricate 3D tissues in
conjuction with microfluidics. In a two-step process, direct cell
writing first creates the 3D tissue and then incorporates a PDMS
device pre-fabricated by soft-lithography64. Current in vitro
models are insufficient for drug screening since the perfusion
and microcirculation methods are inadequate to mimic the true
biological scenario. Recently, ‘tumor-on-a-chip’ based devices
have been coupled with bioprinted vasculatures and lymph
nodes65. This device was a bioprinted blood and a lymphatic
vessel pair (TOC-BBL) model, wherein blood vessels were printed
as hollow perfusable tubes with both ends open whereas lymph
nodes were fabricated as tubes with one side sealed or blinded.
This was achieved by multilayered coaxial, concentric nozzle
assembly and adjustments of the flow rates of the crosslinker and
bioink solutions. The permeability of the vessels were tuned by
selecting optimum bioink compositions. This system was used to
simulate the complex transport mechanism used for drug
screening in cancer microenvironment.
On the corollary, several microfluidic devices can themselves be
fabricated by the use of 3D printing, as exemplified in Fig. 7a, b
(refs. 66,67). Such methodology can be applied to deposit cells with
multi-nozzle deposition systems over channels built by a digital
micro-mirror technique68. Integration of multi-head bioprinting
P Datta et al.
7
Published in partnership with The Hormel Institute, University of Minnesota npj Precision Oncology (2020)    18 
Fig. 4 A 3D bioprinted cervical cancer model. a 3D Hela/hydrogel construct fabricated using EBB. b Schematic representation of 3D printed
construct. c Schematic description of the timeline followed for the fabrication of tissue. 3D bioprinted constructs as well as 2D planar samples
were all cultured for five days followed by paclitaxel addition and culture for the next three days. d Cell morphology after paclitaxel treatment
on 3D bioprinted and 2D planar sample. e Cellular metabolic activity after paclitaxel treatment shows chemoresistance for 3D samples.
f Comparison of spheroid diameters in the hydrogel with and without the addition of paclitaxel. ***p < 0.001 by t-test (scale bar, 50 µm; scale
bar in enlarged images, 20 µm; reproduced/adapted with permission from ref. 51).
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Fig. 5 A 3D bioprinted ovarian cancer model. a GelMA μS loaded with cells. b µS are assembled in the polycaprolactone (PCL) scaffold.
c Assembled PCL scaffold was carefully loaded into a bioreactor, imaged from d top and e bottom, and f, g stained with calcein-AM and propidium
iodide in PBS (both at 1 μgmL−1) for live (green)–dead (red) staining (scale bars, 200 μm; reproduced/adapted with permission from ref. 52).
Fig. 6 Bioprinting a triculture hepatic construct. a Schematic representation of a two-step 3D bioprinting approach, in which hiPSC-HPCs
were patterned by the first digital mask followed by patterning using a second digital mask containing supporting cells. b Grayscale digital
masks designed for two-step bioprinting. The white patterns represent the light reflecting patterns for photopolymerization. c Fluorescent
and bright field Images (5×) of patterns made from fluorescently labeled hiPSC-HPCs (green) in 5% (wt/vol) GelMA, and supporting cells (red)
in 2.5% (wt/vol) GelMA with 1% GMHA on day 0 (scale bars, 500 µm.) d A piece of coverslip containing 3D bioprinted hepatic construct (scale
bar, 5 mm.) e 3D reconstruction of a bioprinted patterned construct (scale bar, 500 µm; reproduced/adapted with permission from ref. 55).
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with a maskless solid-freeform fabrication system was also
developed, which speeded up the fabrication process and
eliminated toxic chemicals. Each 3D print-head can be used to
deposit either of a photoresist for the circuit architecture;
crosslinker for the photopolymer, helium and oxygen plasma
deposition; and finally the bioink deposition inside microchan-
nels69. 3D bioprinting has also been combined with low-
temperature molding using A549/95-D cell and gelatin-sodium
alginate based bioink to develop a model for exploring lung
cancer invasion, where bioprinted cells showed increased migra-
tion potential compared to cells in 2D as determined from
histochemical, scratch test and genetic assays70.
In precision oncology, tumor-on-a-chip models can overcome
the absence of complexity of in vitro models and hence improve
the prediction of drug screening, systemic drug toxicity and
whole-organ drug pharmacology71. While organoid or tumoroid
models rely on self-organization, organ-on-chip models can better
recapitulate tumor microenvironment by providing greater con-
trol over spatial confinement and multi-organ interconnections.
Such models with built-in vasculature can be fabricated enabling
3D parenchymal organization surrounded by endothelial cell-
coated perfusable microchannels, which can be used for studying
perfusability and cancer metastasis in multiple organs. Skardal
et al. have demonstrated a microfluidic device for individualized
therapy by developing a gut cancer metastasis model containing
co-culture of malignant colon cells with epithelial cells on a
thiolated hyaluronic acid, thiolated gelatin, and PEGDA-based
hydrogel. The epithelial cells and transformed colon cancer cells
were used to mimic a primary tumor foci site. The construct was
then connected to a liver HepG2 culture, by a circulating fluid
flow, to act as the secondary metastasis site downstream72. The
mechanical stiffness of these hydrogels could be varied by
changing their degrees of polymerization, which was used to
demonstrate that metastasis potential of the cells increased as the
stiffness of the hydrogel was decreased72.
FUTURE OUTLOOK
3D bioprinting of biomimetic microenvironment
Among different fabrication techniques to recapitulate the
architecture and microenvironment of tumor tissues, 3D bioprint-
ing is advancing at a greater pace73,74. However, challenges still
remain in terms of choice of suitable bioink, bioprinting time,
dimension of bioprinted tissues75, etc. to render truly cancer
mimetic models suitable for industrial applications. From afore-
mentioned examples and studies conducted on different tumor
models, it is evident that selecting a suitable bioink is one of the
most crucial prerequisites for mimicking the tumor microenviron-
ment. Absence of a universal bioink, and hence the use of
customized bioinks and difference in cell seeding densities make
the correlation of the outcomes difficult76. dECM (refs. 77,78) or
spheroids have been recently used as bioinks for developing
in vitro models and maintaining the tumor microenvironment79.
Such dECM plays an important role in revealing cell–ECM and
cell–cell interactions, as well as genetic mutation in culture. The
stimuli-sensitive hydrogel-based bioinks are also used to mimic the
dynamic changes of tumor microenvironment80. However, several
recommendations have already emerged in the literature. For
example, in bioprinting cancer models including co-culture,
scaffold-free bioprinting approach is more suitable, and hence
DBB with low viscosity should be the preferred method. DBB is also
more suitable to create temporo-spatial gradients in drug
administration. DBB with low viscosity bioinks is also advantageous
for HTS since issues of nozzle clogging leading to batch-to-batch
inhomogeneity may be reduced by this method81. 3D organotypic
models comprising the vascular structures are one of the most
realistic models for studying cancer metastasis and anticancer drug
screening. In addition, the other main challenge in the develop-
ment of tumor microenvironment is the use of immortalized cell
lines, which get manipulated in long-term culture conditions as
they undergo numerous passages. On the other hand, patient-
derived primary cells conserve the heterotypic environment of
native tumor niche and are more useful for developing persona-
lized therapeutics43. Though, the ideal bioink for patient-derived
cells are yet to be standardized with respect to efficient mixing of
the components and matching of the mechanical properties.
Bioprinted cancer models as a preclinical screening tool for
immunotherapy
The tumor microenvironment consists of cancer cells, stromal
tissue, and various immune cells, such as T cells and macrophages,
the composition of which may also vary from patient to patient.
The interactions between tumor and immune cells in this
microenvironment is thought to play a critical role in the cancer
Fig. 7 Integration of microfluidic devices with 3D bioprinted organ-on-a-chip models. (a) 3D printing of PDMS-based microfluidic chip
(reproduced/adapted with permission from ref. 66). (b) Schematic representation of the microfluidic biopsy application of 3D printed
conformal chips for isolating biomarkers from the organ cortex (scale bar, 500 μm) (reproduced/adapted with permission from ref. 67).
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development, progression, and control82. In recent years, strate-
gies harnessing tumor-infiltrating T cells have become a
remarkably effective treatment option for a subset of patients
with cancer. In addition, cancer cells often create an immunosup-
pressive microenvironment, which can inhibit the effector
functions of antitumor immune cells. However, many key features
of interactions between cancer and immune cells, and how these
interactions affect tumor growth, are poorly understood. Indeed,
our limited understanding of the complex interplay between the
tumor microenvironment and host immune response is a major
barrier to improving immunotherapeutic strategies, and defining
predictive biomarkers for clinical benefit.
Appropriate balance between suppressive versus cytotoxic
immune responses within the tumor microenvironment correlate
with a good prognosis for cancer patients83,84. Immunocompro-
mised microenvironments that suppress immune responses
benefit cancer, whereas the presence of proinflammatory and
cytotoxic T cells result in better clinical outcomes84. While
recruitment of CD8+ cytotoxic T cells and inflammatory IFN+
CD4+ (Th1) subsets into the tumor microenvironment correlates
with better prognosis, high infiltration of regulatory T cells are
associated with unfavorable prognosis in about half of the cases,
whereas in the other half, they may be associated with good
prognosis or show no impact84. Myeloid lineage cells, such as
macrophages or dendritic cells (DCs), are also found abundantly in
the tumor microenvironment. Although their role is not fully clear,
they impact recruitment of other cells, remodeling the tissue, and
activating or suppressing antitumor T cell responses85.
Patients with several cancer types, such as melanoma, non-
small cell lung cancer, and renal cell carcinoma, have greatly
benefited from checkpoint inhibitor therapy, such as anti-PD1 or
anti-CTLA-4 (refs. 86–89). However, these treatments are only
effective in a subset of patients and other cases, such as breast
cancer, the benefits of immunotherapy are currently under
investigation and not yet clear90. These clinical results highlight
the potential and gaps in our understanding of the molecular and
cellular nature of the tumor–immune interactions within the
tumor microenvironment. Thus, understanding the balance of
immune responses and how inhibitory or stimulatory receptors
modulate T cell activation in a tumor microenvironment could be
critical to improving cancer immunotherapy. Further, in the
different tissues in cancer, T cells and other innate cell types can
exhibit marked differences in phenotype and functions due to
cell-to-cell interactions. Indeed, variations in expression of CD161
(+) nonclassical T cells, CD4+ and CD8+ cells have been identified
in lymph nodes, spleen, the mammary lymph nodes, and the
tumor mass91. To model the spatial compartmentalization and
migration behavior of immune cell leading to the development of
metastasis niches in cancer, microfluidic platforms have already
proved beneficial and their integration with bioprinting is
foreseen92–95. In this regard, bioprinting could be employed to
establish a gradient of antigen-presenting cancer cells encapsu-
lated in a hydrogel. Further, this could potentially be combined
either with microfluidic channels or with channels printed using
sacrificial inks, to establish a dynamic environment within the
hydrogel constructs94,96. Immune cells such as PBMC (ref. 97), DCs,
macrophages, cytotoxic CD8+ T cells could be perfused through
the fabricated channels to study migration of these cells toward
cytokine producing cancer cells93,94. These immune cells have
already shown to play a major role in cancer prognosis98. Stromal
cells such as cancer-associated fibroblasts could also be bioprinted
with the cancer cells to understand their indispensable role in
regulating immune response via the secretion of cytokines99.
However there are several challenges in incorporating dynamic
conditions through mechanically weak hydrogels. A major limita-
tion is maintaining channel integrity over long dynamic culture
periods as cancer cells and stromal cells secrete MMPs, which
gradually degrade the hydrogel microenvironment. Thus,
long-term viability and activity of immune cells under such
conditions would also be affected. Furthermore, bioprinting the
entire model would require combination of several different
bioprinting modalities, such as droplet, extrusion, etc. into one
system, which eventually increases the complexity of the printing.
Thus, manufacturability as well as scalability needs to be overcome
for proper integration of bioprinting and immunotherapy.
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